Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 | Q9Y271 | 3/20 | 0.73 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.73 |
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.73 |
| ▸ | MEN1 | O00255 | 1/20 | 0.73 |
| ▸ | RECQL | P46063 | 1/20 | 0.73 |
| ▸ | BLM | P54132 | 1/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.73 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.73 |
| ▸ | EGFR | P00533 | 1/20 | 0.73 |
| ▸ | ESR1 | P03372 | 1/20 | 0.73 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.73 |
| ▸ | FYN | P06241 | 1/20 | 0.73 |
| ▸ | PGR | P06401 | 1/20 | 0.73 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.73 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.73 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.73 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.73 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.73 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.73 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2850594 | 1.00 | CYSLTR1 (0.73) | CYSLTR1CYP2C8CYSLTR2MEN1RECQL | |
| SCHEMBL2850591 | 1.00 | CYSLTR1 (0.73) | CYSLTR1CYP2C8CYSLTR2MEN1RECQL | |
| SCHEMBL14218222 | 0.91 | CYSLTR1 (0.73) | CYSLTR1CYP2C8CYSLTR2MEN1RECQL | |
| SCHEMBL8497839 | 0.88 | CYSLTR1 (0.77) | CYSLTR1CYP2C8CYSLTR2MEN1RECQL | |
| SCHEMBL8499234 | 0.88 | CYSLTR1 (0.74) | CYSLTR1CYP2C8CYSLTR2MEN1RECQL | |
| SCHEMBL8500042 | 0.88 | CYSLTR1 (0.72) | CYSLTR1CYP2C8CYSLTR2MEN1RECQL | |
| SCHEMBL8496694 | 0.88 | CYSLTR1 (0.72) | CYSLTR1CYP2C8CYSLTR2MEN1RECQL | |
| SCHEMBL8500819 | 0.88 | CYSLTR1 (0.72) | CYSLTR1CYP2C8CYSLTR2MEN1RECQL | |
| SCHEMBL1132498 | 0.87 | — | — | |
| SCHEMBL2547277 | 0.87 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120184000-A1 | KETOREDUCTASE POLYPEPTIDES FOR THE PRODUCTION OF (S,E)-METHYL 2-(3-(3-(2-(7-CHLOROQUINOLIN-2-YL)VINYL)PHENYL)-3-HYDROXYPROPYL)BENZOATE | CODEXIS, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120184000-A1 | KETOREDUCTASE POLYPEPTIDES FOR THE PRODUCTION OF (S,E)-METHYL 2-(3-(3-(2-(7-CHLOROQUINOLIN-2-YL)VINYL)PHENYL)-3-HYDROXYPROPYL)BENZOATE | CODEXIS, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| US-8088610-B2 | Ketoreductases for the production of (S,E)-methyl 2-(3-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-hroxypropyl)benzoate | CODEXIS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088610-B2 | Ketoreductases for the production of (S,E)-methyl 2-(3-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-hroxypropyl)benzoate | CODEXIS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-7786138-B2 | Process for making montelukast and intermediates therefor | SYNTHON BV (NL) | 2010-08-31 | — | — | US | disclosed |
| US-7786138-B2 | Process for making montelukast and intermediates therefor | SYNTHON BV (NL) | 2010-08-31 | — | — | US | disclosed |
| US-20100099879-A1 | PROCESS FOR MAKING MONTELUKAST AND INTERMEDIATES THEREFOR | BENOVSKY PETR | 2010-04-22 | — | — | US | disclosed |
| US-20100099879-A1 | PROCESS FOR MAKING MONTELUKAST AND INTERMEDIATES THEREFOR | BENOVSKY PETR | 2010-04-22 | — | — | US | disclosed |
| US-7601741-B2 | Process for making montelukast and intermediates therefor | SYNTHON BV (NL) | 2009-10-13 | — | — | US | disclosed |
| US-7601741-B2 | Process for making montelukast and intermediates therefor | SYNTHON BV (NL) | 2009-10-13 | — | — | US | disclosed |
| US-7476748-B2 | Process for making montelukast and intermediates therefor | SYNTHON BV (NL) | 2009-01-13 | — | — | US | disclosed |
| US-7476748-B2 | Process for making montelukast and intermediates therefor | SYNTHON BV (NL) | 2009-01-13 | — | — | US | disclosed |
| US-20070135480-A1 | PROCESS FOR MAKING MONTELUKAST AND INTERMEDIATES THEREFOR | SYNTHON BV (NL) | 2007-06-14 | — | — | US | disclosed |
| US-20070135642-A1 | PROCESS FOR MAKING MONTELUKAST AND INTERMEDIATES THEREFOR | SYNTHON BV (NL) | 2007-06-14 | — | — | US | disclosed |
| US-20070135642-A1 | PROCESS FOR MAKING MONTELUKAST AND INTERMEDIATES THEREFOR | SYNTHON BV (NL) | 2007-06-14 | — | — | US | disclosed |
| US-20070135480-A1 | PROCESS FOR MAKING MONTELUKAST AND INTERMEDIATES THEREFOR | SYNTHON BV (NL) | 2007-06-14 | — | — | US | disclosed |
| US-20070135643-A1 | PROCESS FOR MAKING MONTELUKAST AND INTERMEDIATES THEREFOR | SYNTHON BV (NL) | 2007-06-14 | — | — | US | disclosed |
| US-20070135643-A1 | PROCESS FOR MAKING MONTELUKAST AND INTERMEDIATES THEREFOR | SYNTHON BV (NL) | 2007-06-14 | — | — | US | disclosed |
| WO-2007057227-A1 | PROCESS FOR MAKING MONTELUKAST AND INTERMEDIATES THEREFOR | SYNTHON B.V. (NL) | 2007-05-24 | — | — | WO | disclosed |
| WO-2007057225-A2 | PROCESS FOR MAKING MONTELUKAST AND INTERMEDIATES THEREFOR | SYNTHON B.V. (NL) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135480-A1 | PROCESS FOR MAKING MONTELUKAST AND INTERMEDIATES THEREFOR | LTC4S, LTA4H, CYSLTR1 | CYSLTR1 3/4885CYP2C8 773/4885CYSLTR2 10/4885 |
| US-20070135642-A1 | PROCESS FOR MAKING MONTELUKAST AND INTERMEDIATES THEREFOR | CYP4A11, CYP51A1, CYP4F11 | CYSLTR1 9/4885CYP2C8 382/4885CYSLTR2 19/4885 |
| US-20070135643-A1 | PROCESS FOR MAKING MONTELUKAST AND INTERMEDIATES THEREFOR | CMA1, CYP51A1, NOTUM | CYSLTR1 5/4885CYP2C8 792/4885CYSLTR2 11/4885 |
| US-20100099879-A1 | PROCESS FOR MAKING MONTELUKAST AND INTERMEDIATES THEREFOR | CMA1, CYP51A1, NOTUM | CYSLTR1 5/4885CYP2C8 792/4885CYSLTR2 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.